Slu-pp-332 peptide powder

  Product Detail  

SLU-PP-332 More Info

SLU-PP-332 is a pan-agonist of the estrogen receptor-related receptors (EC50’s cell-based cotransfection/reporter assay: ERRα = 98 nM, ERRß = 230 nM, ERRγ = 430 nM) with highest potency for ERRα. Developed to mimic the physiological benefits of exercise, it has shown promise in alleviating conditions such as obesity and metabolic syndrome in preclinical studies. This compound activates all three ERR isoforms, with a slightly higher potency towards ERRα, making it a significant candidate for therapeutic applications in metabolic diseases.

Mechanism of Action

SLU-PP-332 functions by activating ERRs, which are nuclear receptors involved in regulating energy metabolism. Upon administration, it induces a metabolic shift towards increased fatty acid oxidation and energy expenditure, similar to the physiological adaptations observed during exercise. Specifically, studies have shown that SLU-PP-332 leads to:
1. Increased Fatty Acid Oxidation: A 25% increase compared to control groups.
2. Decreased Carbohydrate Utilization: Indicating a preference for lipid metabolism.
3. Enhanced Glucose Uptake: Notably in muscle tissues after prolonged treatment

Applications

SLU-PP-332 has potential applications in:
1. Metabolic Syndrome Treatment: By reducing fat mass and improving insulin sensitivity.
2. Obesity Management: Demonstrating efficacy in mouse models for weight loss and metabolic health improvement.
3. Exercise Mimetic Research: Offering an alternative to physical exercise for those unable to engage in regular activity due to health constraints

Safety and Side Effects

While specific human clinical data on the safety profile of SLU-PP-332 are limited, preclinical studies indicate that it effectively reduces hepatic triglycerides without significant adverse effects noted in animal models. Further research is necessary to fully understand its safety profile and potential side effects in humans.